0001725430 false 0001725430 2022-05-11 2022-05-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549








Date of Report (Date of earliest event reported): May 11, 2022



(Exact name of registrant as specified in its charter)


Delaware   001-39825   82-1512711

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


420 Lexington Ave, Suite 300

New York, NY 10170

(Address of principal executive offices, including zip code)


Registrant’s telephone number, including area code: Telephone: (646) 828-8258



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.01 par value   GBS   The NASDAQ Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.






Item 2.02 Results of Operations and Financial Condition


On May 11, 2022, GBS Inc. (the “Company”) issued a press release (the “Press Release”) announcing financial results for the three months ended March 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.


The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.


Item 9.01. Financial Statements and Exhibits.




Exhibit No.   Description
99.1   Press Release
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: May 11, 2022

  By: /s/ Spiro Sakiris
  Name: Spiro Sakiris
  Title: Chief Financial Officer





Exhibit 99.1



GBS Inc. Reports Third Quarter 2022 Financial Results and
Recent Business Highlights


- Initiated prospective study to collect coincident samples of oral fluid

and blood following IRB approval -


- Finalizing site selection at the University of Newcastle campus for the high-tech manufacturing and production facility -


- $10.76 Million in Cash, Cash Equivalents, and Marketable Securities as of

March 31, 2022, provides estimated runway into H1 2023 -


-To host conference call and webcast today at 4:30 p.m. ET-


New York, NY, May 10, 2022 – GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point-of-care, today announced its financial results for the third quarter ended March 31, 2022 and provided recent business updates.


“This quarter has been extremely productive for the Company as we initiated enrollment of our prospective clinical study following Institutional Review Board approval. This clinical study will provide the robust correlation data required to support future submissions/applications for key regulatory approvals in both the U.S. and Asia,” Interim Chief Executive Officer of GBS, Dr. Steven Boyages stated. “We have carefully designed this trial to ensure that, collectively, the subjects enrolled for clinical investigation represent a cross-section of patients living with type 2 diabetes. The clinical trial site has completed approximately one quarter of the in-clinic portion of the IRB-approved protocol and shipped the first set of samples to Johns Hopkins Hospital, Department of Pathology, where the samples will be analyzed to determine the amount of glucose in oral fluids, venous blood and capillary blood. We remain focused and committed to meeting our milestone targets and look forward to updating the marking on our progress.”


Q3 2022 Recent Developments & Status Updates


Clinical Development


Initiated Trial: Specimen Collection Methodology to Support Subsequent Correlation
  Analyses of Glucose in Oral Fluids, Capillary, and Venous Blood


  The lead clinical trial site will:

    enroll approximately 40 adult subjects diagnosed with type 2 diabetes
    provide adequate distribution of age and sex
    collect and freeze saliva and blood samples for subsequent analysis

  Quest Diagnostics® and the Johns Hopkins Hospital, Department of Pathology, will perform tests on the samples to determine the amount of glucose in oral fluids, venous blood and capillary blood
  GBS will perform subsequent statistical analyses of the correlation of glucose levels
  These data will lead to the development of an algorithm between plasma and salivary glucose





Manufacturing Facility & Equipment Sourcing


  Project development plan underway with objective to commence construction during September 2022
  Initial sourcing for required equipment completed in April. Early equipment acquisition allows for a more efficient build out process while at the same time ensuring the onsite manufacturing equipment is set in preparation for regulatory inspection of the facility.
  Delivery of the initial batch of equipment is expected June 2022


Key Clinical & Operational Milestone Targets


  Initial data from time-course correlation study by July 2022
  Preliminary Biosensor response by September 2022
  Site selection completed with University of Newcastle by August 2022
  Delivery of required equipment for manufacturing build out by December 2022
  Biosensor Algorithm Development by December 2022


Third Quarter 2022 Financial Results


As of March 31, 2022, the Company’s cash, cash equivalents and marketable securities totaled approximately $10.76 million, compared to approximately $12.57 million on June 30, 2021.


For the quarter ended March 31, 2022, the Company had a preliminary net loss of $1.34 million or $0.09 per share, compared to a net loss of $3.14 million or $0.27 per share for the same period in 2021. This is predominantly due to the timing of R&D expenditures and government support income.


As of March 31, 2022, the Company had 14.90 million shares outstanding.


Based on the current operating plan and financial resources, management believes its cash, cash equivalents and marketable securities at March 31, 2021, are sufficient to cover expenses and capital requirements into H1 2023. Our cash runway projection does not include exercising the glucose North American license option agreement.


Conference Call and Webcast


To participate in today’s conference call, please dial 855-327-6837 (Domestic/Toll-Free) or 631-891-4304 (International) and reference the conference ID: 10018968.


To participate via a webcast, please visit: Webcast Registration Link


The webcast will be archived for approximately 30 days and will be available at https://investors.gbs.inc/news-and-events/investor-calendar





About GBS Inc.:


GBS Inc. is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help people living with diabetes.


For more information, please visit GBS.inc or follow GBS Inc. on Twitter and LinkedIn.


Forward-Looking Statements:


Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, GBS Inc.’s ability to develop and commercialize its diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although GBS, Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. GBS Inc. has attempted to identify forward-looking statements by terminology including ‘‘believes,’’ ‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’ ‘‘plans,’’ ‘‘projects,’’ ‘‘intends,’’ ‘‘potential,’’ ‘‘may,’’ ‘‘could,’’ ‘‘might,’’ ‘‘will,’’ ‘‘should,’’ ‘‘approximately’’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in the Company’s public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.


For more information, please contact:


Alex Arzeno – Vice President of IR & Communications

GBS, Inc.



Investor Contact:


Tim McCarthy – Managing Director

LifeSci Advisors, LLC










(Amounts in $)


   Three Months Ended March 31,   Nine Months Ended March 31, 
   2022   2021   2022   2021 
Other income:                    
Government support income  $192,500   $34,290   $370,291   $372,754 
Total revenue   192,500    34,290    370,291    372,754 
Operating expenses:                    
General and administrative   1,122,004    1,013,389    3,457,768    2,205,842 
Development and regulatory approval   413,325    2,156,316    3,161,306    2,529,074 
Prospectus and capital raising   -    5,100    -    358,674 
Total operating expenses   1,535,329    3,174,805    6,619,074    5,093,590 
Loss from operations   (1,342,829)   (3,140,515)   (6,248,783)   (4,720,836)
Other income (expense):                    
Interest expense   (4,217)   (18,561)   (4,892)   (1,091,249)
Loss from unconsolidated equity method investment   -    -    -    (135,692)
Realized foreign exchange income (loss)   10    8,774    (3,094)   (270,333)
Interest income   2,903    7,635    10,973    8,139 
Total other income (expense)   (1,304)   (2,152)   2,987    (1,489,135)
Net loss   (1,344,133)   (3,142,667)   (6,245,796)   (6,209,971)
Net loss attributable to non-controlling interest   (8,887)   (14,854)   (17,900)   (25,684)
Net loss attributable to GBS Inc.  $(1,335,246)  $(3,127,813)  $(6,227,896)  $(6,184,287)
Other comprehensive loss, net of tax:                    
Foreign currency translation loss  $2,793   $(262,032)  $(57,334)  $(278,744)
Total other comprehensive loss   2,793    (262,032)   (57,334)   (278,744)
Comprehensive loss   (1,341,340)   (3,404,699)   (6,303,130)   (6,488,715)
Comprehensive loss attributable to non-controlling interest   (8,887)   (14,854)   (17,900)   (25,684)
Comprehensive loss attributable to GBS Inc  $(1,332,453)  $(3,389,845)  $(6,285,230)  $(6,463,031)
Net loss per share, basic and diluted  $(0.09)  $(0.27)  $(0.43)  $(0.64)
Weighted average shares outstanding, basic and diluted   14,889,904    11,795,741    14,590,656    9,667,399 








(Amounts in $)



March 31,



June 30,


Current assets:          
Cash and cash equivalents  $10,756,089   $12,573,685 
Grant receivable, current portion   1,661,573    2,098,884 
Research and development tax incentive receivable   181,598    1,025,455 
Other current assets   266,163    2,509,017 
Total current assets   12,865,423    18,207,041 
Grant receivable, net of current portion   1,186,838    3,148,328 
Capital work in progress   306,792    - 
Other non-current assets   -    504,000 
TOTAL ASSETS  $14,359,053   $21,859,369 
Current liabilities:          
Accounts payable and accrued expenses  $884,284   $1,467,968 
Related party payables   -    13,323 
Current portion of deferred grant income   3,376,628    2,098,884 
Current employee benefit liabilities   171,263    102,475 
Total current liabilities   4,432,175    3,682,650 
Employee benefit liabilities   36,549    21,770 
Long-term deferred grant income   1,186,838    3,148,328 
Total liabilities   5,655,562    6,852,748 
Commitments and contingencies (Note 9)          
Shareholders’ equity:          
Preferred stock, $0.01 par value, 10,000,000 shares authorized, 0 and 1,300,000 shares issued and outstanding at March 31, 2022 and June 30, 2021, respectively   -    13,000 
Common stock, $0.01 par value, 100,000,000 shares authorized, 14,889,904 and 13,582,122 shares issued and outstanding at March 31, 2022 and June 30, 2021, respectively   148,899    135,821 
Additional paid-in capital   38,440,011    38,440,089 
Accumulated deficit   (29,097,699)   (22,869,803)
Accumulated other comprehensive loss   (718,594)   (661,260)
Total consolidated GBS Inc. equity   8,772,617    15,057,847 
Non-controlling interest   (69,126)   (51,226)
Total shareholders’ equity   8,703,491    15,006,621